CELLINK continues to develop a platform for channeled bioprints suitable for dynamic culture conditions and thereby capable to more closely mimick invivo conditions. This aim involves introducing new 3DBioprinting methods, new printing wells and an inducing Bioink.
PRESS RELEASE Gothenburg, Sweden December 5th, 2018, 08:30 CET CELLINK and Prellis Biologics Inc. sign partnership to commercialize high-resolution holographic bioprinting technology for micro-printing. The partners will utilize their IP, expertise, and know-how to offer the first system enabling ultra-high resolution bioprinting of microstructures such as vascular networks or capillaries. The technology is an important...
PRESS RELEASE Gothenburg, Sweden, December 4th, 2018 CELLINK announces a collaboration with MedImmune to utilize CELLINKs’ 3D-Bioprinting technology for drug discovery Scientists will work side-by-side in MedImmune labs, aiming to speed research and development of new therapies. CELLINK, focused on the development and commercialization of innovative bioprinting technologies, announced today that the company will...
PRESS RELEASE Gothenburg 2018-11-30 CELLINK has entered into an agreement to acquire the Biodispensing company Dispendix GmbH CELLINK AB (“CELLINK”) has entered into an agreement with the owner of Dispendix GmbH. (“Dispendix”) to acquire all shares in Dispendix for a purchase amount of 5 M €(“Acquisition”). “Our innovative products for non-contact, high throughput dispensing and...